About Cytosorbents (NASDAQ:CTSO)
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, the company is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. It has collaboration with Aferetica srl to develop PerLife ex-vivo organ perfusion system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885
Debt
Debt-to-Equity Ratio0.58%
Current Ratio2.64%
Quick Ratio2.54%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.15 million
Price / Sales15.08
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book21.53
Profitability
EPS (Most Recent Fiscal Year)($0.32)
Net Income$-8,460,000.00
Net Margins-52.08%
Return on Equity-118.07%
Return on Assets-40.15%
Miscellaneous
Employees84
Outstanding Shares29,470,000
Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions
What is Cytosorbents' stock symbol?
Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."
How were Cytosorbents' earnings last quarter?
Cytosorbents Co. (NASDAQ:CTSO) announced its quarterly earnings data on Thursday, March, 8th. The medical research company reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.02. The medical research company earned $4.65 million during the quarter, compared to analysts' expectations of $4.56 million. Cytosorbents had a negative net margin of 52.08% and a negative return on equity of 118.07%. View Cytosorbents' Earnings History.
When is Cytosorbents' next earnings date?
What price target have analysts set for CTSO?
5 analysts have issued 12-month target prices for Cytosorbents' shares. Their forecasts range from $9.00 to $14.00. On average, they anticipate Cytosorbents' share price to reach $11.05 in the next year. View Analyst Ratings for Cytosorbents.
Who are some of Cytosorbents' key competitors?
Some companies that are related to Cytosorbents include Inovio Pharmaceuticals (INO), Accuray (ARAY), Utah Medical Products (UTMD), Antares Pharma (ATRS), Endologix (ELGX), GenMark Diagnostics (GNMK), Tandem Diabetes Care (TNDM), Pulse Biosciences (PLSE), Orthopediatrics (KIDS), T2 Biosystems (TTOO), Nuvectra (NVTR), SeaSpine (SPNE), Iradimed (IRMD), Restoration Robotics (HAIR), Apollo Endosurgery (APEN), Alphatec (ATEC), Invuity (IVTY) and Obalon Therapeutics (OBLN).
Who are Cytosorbents' key executives?
Cytosorbents' management team includes the folowing people:
- Dr. Phillip P. Chan M.D., Ph.D., CEO, Pres & Director (Age 48)
- Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 63)
- Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 60)
- Dr. Robert H. Bartlett M.D., Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 79)
- Dr. Christian Steiner M.D., VP of Sales & Marketing
Has Cytosorbents been receiving favorable news coverage?
News articles about CTSO stock have been trending somewhat positive on Friday, Accern reports. The research firm scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytosorbents earned a coverage optimism score of 0.20 on Accern's scale. They also assigned media stories about the medical research company an impact score of 46.08 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Cytosorbents?
Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytosorbents' stock price today?
One share of CTSO stock can currently be purchased for approximately $7.75.
How big of a company is Cytosorbents?
Cytosorbents has a market capitalization of $238.72 million and generates $15.15 million in revenue each year. The medical research company earns $-8,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 84 workers across the globe.
How can I contact Cytosorbents?
Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]
MarketBeat Community Rating for Cytosorbents (CTSO)
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cytosorbents (NASDAQ:CTSO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Cytosorbents in the last 12 months. Their average twelve-month price target is $11.05, suggesting that the stock has a possible upside of 42.58%. The high price target for CTSO is $14.00 and the low price target for CTSO is $9.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.05 | $11.05 | $10.60 | $10.45 |
| Price Target Upside: | 42.58% upside | 39.87% upside | 41.33% upside | 72.73% upside |
Cytosorbents (NASDAQ:CTSO) Consensus Price Target History
Cytosorbents (NASDAQ:CTSO) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Cytosorbents (NASDAQ:CTSO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cytosorbents (NASDAQ CTSO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 10.85%
Cytosorbents (NASDAQ CTSO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | Kathleen P Bloch | CFO | Sell | 120 | $8.25 | $990.00 | 253,424 |  |
| 3/15/2018 | Kathleen P Bloch | CFO | Sell | 11,176 | $8.25 | $92,202.00 | 261,246 | |
| 3/13/2018 | Kathleen P Bloch | CFO | Sell | 1,104 | $8.25 | $9,108.00 | 251,174 | |
| 2/21/2018 | Kathleen P Bloch | CFO | Sell | 10,000 | $8.00 | $80,000.00 | 268,870 | |
| 1/12/2018 | Kathleen P Bloch | CFO | Sell | 12,400 | $7.75 | $96,100.00 | 241,038 | |
| 1/8/2018 | Kathleen P Bloch | CFO | Sell | 32,400 | $7.30 | $236,520.00 | 248,638 | |
| 11/27/2017 | Vincent Capponi | COO | Sell | 4,000 | $7.00 | $28,000.00 | 271,062 | |
| 6/9/2017 | Eric R Mortensen | Insider | Buy | 2,500 | $4.04 | $10,100.00 | 2,500 | |
| 6/9/2017 | Michael G. Bator | Director | Buy | 1,500 | $4.12 | $6,180.00 | | |
| 6/8/2017 | Phillip P. Chan | Insider | Buy | 3,700 | $4.00 | $14,800.00 | | |
| 6/8/2017 | Vincent Capponi | COO | Buy | 2,500 | $4.00 | $10,000.00 | | |
| 6/5/2017 | Phillip P. Chan | Insider | Buy | 6,300 | $4.00 | $25,200.00 | | |
| 5/15/2017 | Kathleen P. Bloch | CFO | Buy | 1,000 | $4.34 | $4,340.00 | | |
| 12/9/2016 | Phillip P. Chan | Insider | Buy | 4,600 | $5.40 | $24,840.00 | | |
| 12/6/2016 | Kathleen P Bloch | CFO | Buy | 1,000 | $4.83 | $4,830.00 | 122,325 | |
| 8/24/2016 | Phillip P Chan | Insider | Buy | 5,000 | $4.89 | $24,450.00 | 121,648 | |
| 6/7/2016 | Michael G Bator | Director | Buy | 3,000 | $4.88 | $14,640.00 | 3,000 | |
| 10/29/2015 | Vincent Capponi | COO | Sell | 4,000 | $7.50 | $30,000.00 | 16,724 | |
| 10/15/2015 | Al Kraus | Director | Sell | 6,774 | $6.22 | $42,134.28 | 55,746 | |
| 10/8/2015 | Al Kraus | Director | Sell | 10,000 | $6.39 | $63,900.00 | 55,746 | |
| 10/1/2015 | Al Kraus | Director | Sell | 10,000 | $6.26 | $62,600.00 | 55,746 | |
| 9/24/2015 | Al Kraus | Director | Sell | 10,000 | $6.44 | $64,400.00 | 55,746 | |
| 9/17/2015 | Al Kraus | Director | Sell | 10,000 | $6.64 | $66,400.00 | 55,746 | |
| 9/10/2015 | Al Kraus | Director | Sell | 10,000 | $7.26 | $72,600.00 | 55,746 | |
| 9/3/2015 | Al Kraus | Director | Sell | 10,000 | $7.26 | $72,600.00 | 55,746 | |
| 8/27/2015 | Al Kraus | Director | Sell | 10,000 | $6.39 | $63,900.00 | 55,746 | |
| 8/20/2015 | Al Kraus | Director | Sell | 10,000 | $7.26 | $72,600.00 | 55,746 | |
| 8/13/2015 | Al Kraus | Director | Sell | 10,000 | $6.26 | $62,600.00 | | |
| 7/23/2015 | Al Kraus | Director | Sell | 10,000 | $6.28 | $62,800.00 | | |
| 7/16/2015 | Al Kraus | Director | Sell | 10,000 | $6.33 | $63,300.00 | | |
| 7/9/2015 | Al Kraus | Director | Sell | 10,000 | $5.98 | $59,800.00 | | |
| 7/2/2015 | Al Kraus | Director | Sell | 10,000 | $6.29 | $62,900.00 | | |
| 6/25/2015 | Al Kraus | Director | Sell | 13,205 | $7.33 | $96,792.65 | | |
| 6/18/2015 | Al Kraus | Director | Sell | 10,000 | $5.78 | $57,800.00 | | |
| 6/11/2015 | Al Kraus | Director | Sell | 10,000 | $6.29 | $62,900.00 | | |
| 6/4/2015 | Al Kraus | Director | Sell | 10,000 | $6.30 | $63,000.00 | | |
| 5/28/2015 | Al Kraus | Director | Sell | 10,000 | $6.32 | $63,200.00 | | |
| 11/17/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 11/10/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 11/3/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 10/27/2014 | Al Kraus | Director | Sell | 100,000 | $0.24 | $24,000.00 | | |
| 10/10/2014 | James T Gunton | Director | Sell | 1,240,762 | $0.24 | $297,782.88 | | |
| 10/6/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 9/29/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 9/25/2014 | Al Kraus | Director | Sell | 41,500 | $0.23 | $9,545.00 | | |
| 9/22/2014 | Al Kraus | Director | Sell | 8,500 | $0.23 | $1,955.00 | | |
| 9/15/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 9/12/2014 | James T Gunton | Director | Sell | 30,450 | $0.24 | $7,308.00 | | |
| 9/8/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 9/5/2014 | James T Gunton | Director | Sell | 100,000 | $0.24 | $24,000.00 | | |
| 9/2/2014 | Al Kraus | Director | Sell | 50,000 | $0.25 | $12,500.00 | | |
| 9/2/2014 | Kathleen P Bloch | CFO | Buy | 65,000 | $0.23 | $14,950.00 | | |
| 8/28/2014 | James T Gunton | Director | Sell | 214,387 | $0.24 | $51,452.88 | | |
| 8/27/2014 | James T Gunton | Director | Sell | 1,360,000 | $0.24 | $326,400.00 | | |
| 8/25/2014 | Al Kraus | Director | Sell | 100,000 | $0.25 | $25,000.00 | | |
| 8/18/2014 | Al Kraus | Director | Sell | 100,000 | $0.27 | $27,000.00 | | |
| 8/11/2014 | Al Kraus | Director | Sell | 100,000 | $0.28 | $28,000.00 | | |
| 8/4/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | | |
| 7/21/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | | |
| 7/10/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | | |
| 7/7/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | | |
| 6/23/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | | |
| 6/18/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | | |
| 5/20/2014 | Kathleen P Bloch | CFO | Buy | 110,000 | $0.24 | $26,400.00 | | |
| 9/4/2012 | Phillip P Chan | CEO | Buy | 190,000 | $0.13 | $24,700.00 | | |
(Data available from 1/1/2013 forward)
Cytosorbents (NASDAQ CTSO) News Headlines
| Source: |
|
Cytosorbents (NASDAQ:CTSO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cytosorbents (NASDAQ:CTSO) Income Statement, Balance Sheet and Cash Flow Statement
Cytosorbents (NASDAQ CTSO) Stock Chart for Friday, April, 20, 2018
Loading chart…
